Today's News | Note: News feeds may no longer be available for the articles on this page.

Pharmasset cancels hepatitis drug development 7:49 AM 4/20/2009
Forbes - NY,USA
Pharmasset Inc ends development of its most advanced drug candidate clevudine. There are concerns of severe muscle weakness in hepatitis B patients. ...

Glaxo Nears $3 Billion Stiefel Deal 4:54 PM 4/19/2009
Wall Street Journal - USA
GlaxoSmithKline PLC is close to a deal to acquire a US maker of dermatology products. Stiefel Laboratories Inc is part-owned by US buyout firm Blackstone Group LP. GSK may be offering about $3 billion. ...

Bone drugs may protect against radiation exposure 2:03 PM 4/19/2009
Reuters - USA
Bisphosphonates drugs used to strengthen bones to prevent osteoporosis delayed and sometimes prevented mice exposed to high doses of radiation from developing leukemia. ...

Biogen Says Sixth MS Patient On Tysabri Gets Brain Infection 4:39 PM 4/17/2009
Wall Street Journal - USA
Biogen Idec Inc disclosed that a sixth multiple-sclerosis patient on Tysabri has developed progressive multifocal leukoencephalopathy (PML) since the drug was reintroduced on the market in 2006. ...

Heroin Addiction Drug May Relieve Symptoms of Fibromyalgia 3:41 PM 4/17/2009
Scientific American - USA
Naltrexone commonly used to treat heroin addiction appears to ease the symptoms of fibromyalgia reducing pain and fatigue. ...

StemCells shares gain ground on licensing deal 9:16 AM 4/16/2009
Forbes - NY,USA
StemCells Inc signed a non-exclusive licensing deal with a major pharmaceutical company without disclosing the name of the company or financial details of the agreement. ...

Glaxo and Pfizer create new HIV drug company 6:09 AM 4/16/2009
The Associated Press
GlaxoSmithKline PLC and Pfizer Inc plan to create a new company to invest in the research and development of HIV treatments. Glaxo will initially hold 85 percent equity with Pfizer holding the rest. ...

Infinity stops cancer drug trial, shares sink 4:20 PM 4/15/2009
Reuters - USA
Infinity Pharmaceuticals Inc halted a late-stage study of its cancer drug IPI-504 for gastrointestinal stromal tumors (GIST). Review showed an higher-than-expected death rate among patients receiving the drug. ...

New Drug Being Tested for Pancreatic Cancer 3:10 PM 4/15/2009
Forbes - NY,USA
Amgen's drug AMG 479 designed to inhibit the activity of insulin-like growth factors IGF-1 and IGF-2 appeared to reduce pancreatic cancer growth in laboratory tests. ...

Japan's Santen licenses glaucoma drug to Merck & Co 7:50 AM 4/15/2009
Reuters - USA
Japan's Santen Pharmaceutical Co agreed to license its glaucoma and ocular hypertension drug tafluprost to Merck & Co. ...

Sanofi to Buy BiPar, Boosting Cancer Drug Potential 6:45 AM 4/15/2009
Bloomberg - USA
Sanofi-Aventis SA will buy US biopharmaceutical company BiPar Sciences Inc. The deal includes payments up to $500 million in milestonses for BiPar’s BSI-201 drug candidate in mid-stage testing for breast, ovarian, and other cancers. ...

Dendreon Triples After Successful Cancer Drug Study 3:49 PM 4/14/2009
Bloomberg - USA
Dendreon Corp said its experimental prostate cancer drug Provenge significantly prolonged survival in a study designed for US FDA approval. ...

Novartis MS drug linked to new side effect 8:52 AM 4/14/2009
Reuters - USA
Novartis AG's experimental oral multiple sclerosis (MS) drug FTY720 is linked to a case of hemorrhaging focal encephalitis. ...

Roche Sues Mylan to Block Generic Version of Xeloda Cancer Drug 7:49 AM 4/14/2009
Bloomberg - USA
Roche Holding AG is suing Mylan Inc to prevent it from selling a generic version of its Xeloda (capecitabine) breast cancer drug. Roche wants a court to block approval until a patent expires in 2013. ...

Ipsen in anti-wrinkle drug side-effect talks in US 5:40 AM 4/14/2009
Reuters - USA
Ipsen and Medicis Pharmaceutical Corp need to detail possible side effects of its anti-wrinkle drug Reloxin before it can win final marketing approval. ...

<- Day Earlier | Today's News